Summary
Introduction
The ability to alter the clinical course or eventual disability disease activity are required that are related to, but more sensitive than, clinical measures. Such techniques would in multiple sclerosis is generally agreed to be the definitive outcome measure for assessment of potential new therapies allow more rapid screening of new therapies in exploratory (phase I/II) trials, in addition to acting as supplementary Rudick et al., 1996) . Nevertheless, because the clinical course is highly variable, markers of markers of disease activity in definitive (phase III) studies where a clinical end-point is the primary outcome measure. gadolinium chelates within the lesion, resulting in an increased rate of T 1 relaxation (i.e. a shorter T 1 relaxation In relapsing-remitting and secondary progressive multiple sclerosis, serial T 2 -weighted MRI reveals 5-10 times as many time) and higher signal on T 1 -weighted images. An alternative method for improving enhancing lesion new lesions as there are clinical relapses (Willoughby et al., 1989; Thompson et al., 1991) . Gadolinium-diethyleneconspicuity relies on decreasing the signal of surrounding brain parenchyma using MT contrast (Balaban and Ceckler., triaminepenta-acetic acid (Gd-DTPA) enhancement, by detecting blood-brain barrier breakdown and inflammation 1992). This technique relies on cross-relaxation between mobile 'free' water protons and 'bound' protons associated in new and reactivated chronic lesions (Hawkins et al., 1990; Kermode et al., 1990a, b; Katz et al., 1993) , further increases with macromolecules such as proteins and cell membrane constituents (Wolff and Balaban, 1989; Balaban and Ceckler, the reliability and sensitivity of detecting active lesions Miller, 1994) . In relapsing-remitting and 1992). By using an off-resonance MT presaturation pulse, it is possible to saturate the broad resonance of the bound secondary progressive multiple sclerosis, the presence of such enhancement is more frequent during relapse and proton pool, with consequent exchange of magnetization and reduction in the free water signal. In normal brain, this results correlates well with clinical activity (Gonzalez-Scarano et al., 1987; Thompson et al., 1991 Thompson et al., , 1992 Smith et al., 1993; in decreased signal intensity of brain parenchyma, especially white matter. Although MT presaturation will also reduce et al., 1994) . In addition, for patients with relapsing-remitting and secondary progressive multiple sclerosis, short-term serial the signal intensity of free water protons adjacent to gadolinium, this reduction is small compared with that in normal measurement of the number of Gd-DTPA-enhancing lesions may have a predictive value for long-term clinical outcome tissue (Mehta et al., 1995) . Several studies have reported improved conspicuity of gadolinium-enhancing lesions in (Losseff et al., 1996a, b) . In benign multiple sclerosis, where there is relatively little clinical deterioration over time, multiple sclerosis using MT contrast (Tanttu et al., 1992; Finelli et al., 1994; Mehta et al., 1995) . To date, however, longitudinal studies using conventional doses of Gd-DTPA have revealed much lower rates of activity than those seen no investigators have compared or combined triple-dose Gd-DTPA and MT imaging directly in the same multiple in relapsing-remitting multiple sclerosis (Thompson et al., 1992; . For patients with primary progressive sclerosis patients. By combining these methods, the aim of this study was to optimize sensitivity to detection of bloodmultiple sclerosis, few new lesions are usually seen on monthly T 2 -weighted images and there is usually little or no brain barrier breakdown. Such optimization would be of potent value both for treatment trials, allowing shorter and enhancement with conventional doses of Gd-DTPA, despite steady clinical deterioration (Thompson et al., 1991) .
smaller exploratory (phase I/II) studies and, for clinical practice, where diagnostic accuracy might be improved. Any Several methods have been proposed to increase the conspicuity of gadolinium-enhancing lesions in a variety of potential increase in sensitivity may be useful in furthering our understanding of the pathogenesis of multiple sclerosis; neurological diseases, including multiple sclerosis. These include the use of a higher (0.3 mmol/kg) dose of Gd-DTPA, this is especially relevant for the primary progressive form of disease, where serial MRI studies of the brain and spinal introduction of a delay between contrast-medium injection and imaging, and the utilization of magnetization transfer cord using 0.1 mmol/kg Gd-DTPA have detected little or no blood-brain barrier breakdown despite steady clinical (MT) contrast.
With regard to the dose of gadolinium chelates used, deterioration (Thompson et al., 1991; Kidd et al., 1996) . We have prospectively studied the individual and combined several groups have shown that a dose higher than 0.1 mmol/ kg may be beneficial for improved detection of enhancing effects of Gd-DTPA dose (0.1 mmol/kg versus 0.3 mmol/ kg) and MT contrast on enhancing lesion conspicuity in lesions in various neurological disorders, including multiple sclerosis (Runge et al., 1991; Yuh et al., 1991;  Haustein multiple sclerosis. In addition, we have attempted to determine the optimal time for imaging, following contrastet al., 1993; Mathews et al., 1994; Wolansky et al., 1994; Filippi et al., 1995 Filippi et al., , 1996a . Although experience is medium injection for each of these methods. relatively limited, this higher dose of Gd-DTPA does not appear to result in more side effects than standard doses (Haustein et al., 1993) . The optimal time for imaging after
Material and methods
contrast-medium injection is not clear, although dynamic studies in multiple sclerosis with 0.1-0.2 mmol/kg Gd-
Subjects
Fifty patients aged 24-56 years with clinically definite DTPA have shown marked lesion heterogeneity with maximal intensity occurring anytime between 4 min and 2 h (Kermode multiple sclerosis (Poser et al, 1983) were recruited from the population of patients attending the out-patient department et al ., 1990) . Studies in primary progressive and benign multiple sclerosis have shown possible small advantages in of the National Hospital for Neurology and Neurosurgery; 14 had relapsing-remitting multiple sclerosis, defined as a using a 1 h delay after contrast-medium injection (Filippi et al., 1995 (Filippi et al., , 1996b . The mechanisms whereby higher conhistory of relapses and remissions either occurring for Ͻ10 years or with disability on the Kurtzke Expanded Disability trast-medium doses and delayed imaging result in improved detection are likely to rely on increased concentration of Status Scale (EDSS) (Kurtzke, 1983) Ͼ3; seven had benign multiple sclerosis, as defined by a relapsing-remitting course previous experiment to cause low-signal lesions on T 1 -weighted images almost to disappear with MT presaturation, for Ͼ10 years with EDSS ഛ 3; 10 had secondary progressive multiple sclerosis, as defined by an initial relapsing-remitting without allowing lesions to become hyperintense. Without moving the patient, Gd-DTPA contrast-medium was adminiscourse followed by a subsequent progressive neurological deterioration for at least 6 months with or without tered as a bolus, followed by 5 ml normal saline via the long line. Imaging resumed with T 1 -weighted sequences superimposed relapses; 16 patients had primary progressive multiple sclerosis, as defined by a progressive neurological identical to those attained pre-injection, alternating MT and non-MT acquisitions over 1 h. This resulted in pairs of deterioration from onset, without relapse or remission; three patients were classified as having transitional multiple MT and non-MT studies at three time points [early (first 20 min), short-delay (20-40 min) and long-delay (40-sclerosis, as defined by a single transient episode consistent with demyelination followed by a progressive neurological 60 min)] for each dose of Gd-DTPA. Contrast-enhanced imaging commenced with or without MT in alternate patients, deterioration, without relapse or remission.
All patients underwent a detailed history and complete and this sequence remained constant for both sessions. All patients were initially blinded to Gd-DTPA dose neurological examination by one observer (N.C.S.). Patients were classified as above and disability was scored with the administered for the first session (0.3 mmol/kg) and were all asked an open-ended question regarding any adverse events EDSS and Kurtzke's functional score (Kurtzke, 1983) . In addition, the classification of all the patients was critically after imaging and again at the second session 24-72 h later. For the second session (0.1 mmol/kg Gd-DTPA), those reviewed by an experienced neurologist. Exclusion criteria included pregnancy, breastfeeding, a history of allergy, any patients who had suffered possible adverse events following the triple-dose and were worried about further contrast previous adverse reaction to contrast media, current asthma, or any history of asthma requiring hospital admission. No administration were unblinded before having the single dose. All patients were asked to contact us if they suffered any patients were admitted to the study within 1 month of a clinical relapse. In addition, no patients had received steroids adverse events following the second session (0.1 mmol/kg). For all imaging, patients were repositioned using techwithin the previous month or other immunosuppressive therapy within the previous 6 months.
niques described elsewhere (Gallagher et al., 1997) . To minimize artefactual contrast variations on the processed All patients gave written, informed consent to participate in the study, which had been approved by the joint ethics films, transmitter and receiver gains were manually standardized for all the non-MT acquisitions at both sessions, and committee of the Institute of Neurology and the National Hospital for Neurology and Neurosurgery.
separately standardized for MT acquisitions. In addition, window levels were manually set separately for MT and non-MT unenhanced images to allow optimal contrast for each type of scan. These window levels remained identical for the
MRI protocol
All imaging was carried out with a 1.5 Tesla superconducting comparable pre-and post-injection images at each session. All images were assessed by one experienced neurosystem using a standard quadrature headcoil. Patients were imaged with identical protocols on two separate days (24-radiologist (C.D.G.) who was blinded to patient identity, all clinical information, Gd-DTPA dose and imaging details 72 h apart, consecutive where possible). The only difference between these two sessions was the dose of Gd-DTPA used (delay and MT). Because MT images resulted in loss of contrast between grey and white matter, an element of (0.3 mmol/kg on the first day and 0.1 mmol/kg on the second day).
unblinding was unavoidable. Unenhanced non-MT T 1 -weighted images acquired at the second imaging session First, T 2 -and proton-density weighted images of the brain were acquired using a dual fast-spin echo sequence were assessed for all patients. No patient showed evidence of residual Gd-DTPA enhancement. Unenhanced MT-pre-(TR 3020 ms, TE ef 19 and 90 ms, 46 contiguous 3 mm axial oblique slices, echo train length 8, 256 ϫ 256-pixel image pared T 1 -weighted images were assessed for evidence of high lesion signal that might make assessment of the contrastmatrix, 24 ϫ 18 cm 2 field of view, acquisition time 8 min). The patient was then removed from the imager and an enhanced study more difficult. This was observed in only three patients (one each with transitional, relapsing-remitting intravenous cannula was inserted. A long line was attached to the cannula and flushed with normal saline. Imaging and secondary progressive multiple sclerosis), and in each case it affected only a single lesion. In five patients (one resumed with a pair of T 1 -weighted images (spin echo, TR 600 ms, TE 17 ms, 46 contiguous 3 mm axial oblique slices, with relapsing-remitting, three with secondary progressive and one with primary progressive multiple sclerosis) the one excitation, 256 ϫ 256-pixel image matrix, 24 ϫ 18cm 2 field of view), acquired separately, with and without MT normal-appearing white matter surrounding lesions (as assessed on the T 2 -weighted images) appeared as a faint presaturation. Acquisition time was 8 min 11 s for non-MT and 10 min 18 s for the MT-prepared scans. For presaturation, bright rim. This phenomenon was also seen on some comparable non-MT T 1 -weighted images, although it was less a Hamming apodized 3-lobe sinc pulse, duration 12 ms and peak amplitude equivalent to a 520°_flip angle, was applied notable. Contrast-enhanced non-MT and MT-prepared T 1 -weighted images were analysed individually in a random 1 kHz off resonance; this sequence had been optimized in a order (patients, Gd-DTPA dose and acquisition modality). All kg Gd-DTPA), urinary difficulties in three patients (urgency, frequency or incontinence), and practical difficulties in three contrast-enhanced studies were assessed with the comparable unenhanced MT/non-MT image for evidence of enhancing patients (lack of time or imager failure). One patient with an incomplete study due to imager failure noticed flushing and lesions. Before commencing the analysis, films from 15 patients studied were assessed both by the study rater (C.D.G.)
paraesthesiae following the 0.3 mmol/kg Gd-DTPA. One patient who completed the protocol noticed a dry mouth and a separate experienced neuroradiologist (I.F.M.) to standardize the criteria for definiton of enhancing lesions and to immediately following contrast-medium injection on both days of the study. Two patients suffered from gastrointestinal ensure reliable observer agreement. Strict criteria were applied to the designation of an enhancing lesion: all 'definite' upsets a few hours following the first study with 0.3 mmol/ kg Gd-DTPA (diarrhoea in one and diarrhoea with vomiting enhancing lesions were included, whereas areas of bright signal indistinguishable from flow artefact or Gd-DTPA in the other); they experienced no adverse events following the lower dose of contrast medium. Overall, seven of the 50 contrast within vessels, without comparable high signal on T 2 -or proton density-weighted images, were excluded. None patients (14%) who received the triple dose suffered adverse events possibly related to Gd-DTPA (allergic reaction, of the high-signal regions noted on unenhanced MT images, described above, appeared to change in signal intensity flushing with paraesthesiae, flushing and a sensation of facial congestion followed by headache, diarrhoea, diarrhoea and following contrast medium, and were not found, in retrospect, to be enhanced on any non-MT images.
vomiting, vomiting following contrast-medium injection, or dry mouth immediately following contrast-medium injection). Only one of the 48 patients (2%) who received the single dose suffered an adverse event possibly related to Gd-DTPA,
Statistical analysis
MRI data were analysed using the Wilcoxon matched-pairs namely a dry mouth immediately following contrast-medium injection. signed rank sum test.
Results

MRI data
Figure 1 allows a comparison of all imaging protocols in the
Clinical data
31 patients who completed the full study (four with benign, Of the 50 patients recruited (Table 1) , 19 patients (three with nine with relapsing-remitting, five with secondary benign, five with relapsing-remitting, five with secondary progressive, 10 with primary progressive and three with progressive, and six with primary progressive multiple transitional multiple sclerosis). To assess the individual and sclerosis) failed to complete the full protocol. Of these, combined effects of MT, delayed imaging and Gd-DTPA six were imaged before the MT sequence was available.
contrast-medium dose, data from all the patients entered into Two patients did not have a second imaging session with the study is presented. 0.1 mmol/kg Gd-DTPA. In one case this was due to claustrophobia. The other patient developed an urticarial rash and penile swelling after the first session and was excluded from a second. Both adverse events in this patient were mild
Effects of Gd-DTPA contrast-medium dose
Early contrast-enhanced T 1 -weighted non-MT images were and settled spontaneously within 2 days, although he went on to develop septicaemia secondary to a urinary tract assessed in all multiple sclerosis subgroups to evaluate the effect of 0.3 mmol/kg (triple-dose) versus 0.1 mmol/kg infection. Part of one patient's imaging was omitted due to vomiting immediately following injection of 0.3 mmol/kg (single-dose) Gd-DTPA (Table 2 ). The use of the triple dose in 48 patients studied (seven with benign, 13 with relapsingGd-DTPA; there were no adverse events after the next day's dose of 0.1 mmol/kg Gd-DTPA. Causes for the other remitting, nine with secondary progressive, 16 with primary progressive and three with transitional multiple sclerosis) incomplete studies included discomfort or spasms in three patients, headache associated with flushing and a subjective resulted in an overall 75% increase in the number of enhancing lesions detected (132 with the single dose versus 231 with sensation of facial congestion in one patient (after 0.3 mmol/ Short delay (imaging at 20-40 min) . The effect of a relapsing-remitting multiple sclerosis showed 10 enhancing short delay for both single and triple doses of Gd-DTPA lesions with the triple dose and 11 with the single dose and contrast-medium was assessed in 44 patients who had all a patient with primary progressive multiple sclerosis who such studies (six with benign, 12 with relapsing-remitting, underwent the full protocol showed a single enhancing nine with secondary progressive, 14 with primary progressive lesion with early single-dose imaging not observed on any and three with transitional multiple sclerosis). With early other study.
single-dose imaging a total of 131 enhancing lesions was The number of patients with an 'active' study, as defined by detected within 14 active studies. With a short delay in the presence of one or more enhancing lesions, increased imaging, 165 enhancing lesions were detected within 15 from 15 to 17 (three patients with benign multiple sclerosis active studies (one patient each with benign, relapsingwere 'active' only with the triple dose and one patient with remitting and secondary progressive multiple sclerosis were primary progressive multiple sclerosis was active only with active only with delayed imaging; one patient each with the single dose).
benign and primary progressive multiple sclerosis were active In individual multiple sclerosis subgroups, triple-dose only with early imaging). In the same patients, early tripleimaging increased detection of enhancing lesions in patients dose imaging showed 225 enhancing lesions within 15 active with benign, relapsing-remitting and secondary progresstudies. Further addition of a short delay to triple-dose sive multiple sclerosis; this was significant only in patients imaging showed 243 enhancing lesions within 18 active with relapsing-remitting multiple sclerosis (86 versus 46 studies (one patient each with relapsing-remitting, secondary enhancing lesions in 13 patients, P Ͻ 0.05, Wilcoxon progressive and transitional multiple sclerosis were active matched-pairs signed rank sum test).
only with delayed imaging). The overall trend for short-delay imaging to increase the number of enhancing lesions detected was not statistically significant for either single-dose or tripledose studies.
Long delay (imaging at 40-60 min).
The effect of long delay for both single and triple doses of Gd-DTPA contrast-medium was assessed in 35 patients who had all such studies (five with benign, nine with relapsing-remitting, seven with secondary progressive, 11 with primary progressive and three with transitional multiple sclerosis).
With early single-dose imaging, 88 enhancing lesions were detected within eight active studies. With a long delay in imaging, 113 enhancing lesions were detected within eight active studies (one patient with benign multiple sclerosis was within nine active studies; with long-delay triple-dose imaging The combination of MT with short-delay imaging was assessed for 40 patients in single-dose (Table 3 ) and 41 patients in triple-dose studies (Table 4) . Compared with early
Effects of MT imaging
non-MT imaging, significantly more enhancing lesions were The individual effect of MT imaging was assessed at the detected with this combined approach (P Ͻ 0.05 for singleearly time (0-20 min post contrast) for both single-and dose studies and P Ͻ 0.01 for triple-dose studies, Wilcoxon triple-dose studies in 42 patients (six with benign, 10 with matched-pairs signed rank sum test). For the single dose relapsing-remitting, seven with secondary progressive, 16 there was no difference in the overall number of active with primary progressive and three with transitional multiple studies, although one patient with primary progressive sclerosis) (see Fig. 2 ). With conventional single-dose nonmultiple sclerosis showed activity only on the early, non-MT MT imaging, a total of 90 enhancing lesions was detected images. For the triple dose, the combination of MT and short within 10 active studies. With single-dose MT imaging 119 delays resulted in three additional active studies (from 10 enhancing lesions were detected within 12 active studies (one to 13). patient each with benign, relapsing-remitting and primary At both doses of contrast medium, there were no significant progressive multiple sclerosis were active only with MT differences between short and long delay for detecting imaging; one patient with primary progressive multiple enhancing lesions [130 (short delay) versus 126 (long delay) sclerosis showed a single enhancing lesion only with nonenhancing lesions in 34 patients in the single-dose studies, MT imaging). In the same patients, triple-dose non-MT and 186 (short delay) versus 194 (long delay) enhancing imaging showed 156 enhancing lesions within 12 active lesions in 35 patients in the triple-dose studies]. studies. With triple-dose MT imaging 169 enhancing For individual benign, relapsing-remitting and secondary lesions were detected within 15 active studies (one patient progressive subgroups, MT imaging with either short or long delay increased the overall number of enhancing lesions each with relapsing-remitting, secondary progressive, detected for both single-and triple-dose studies, although primary progressive and transitional multiple sclerosis were these increases were not statistically significant. active only with MT imaging; one patient with benign multiple sclerosis showed a single enhancing lesion only with non-MT imaging). The overall trend for MT imaging
Comparison of delayed MT (single-dose) and to increase the number of enhancing lesions detected was early non-MT imaging (triple-dose Gd-DTPA)
not statistically significant for either single-dose or triple-
The effects of combined MT and short-delay imaging (the dose studies.
most sensitive of the single-dose studies) were compared Within this patient group, the effect of MT imaging was with those of early non-MT imaging following the triple variable. With single-dose studies, MT imaging increased dose in 40 patients (five with benign, 10 with relapsingdetection of enhancing lesions in seven patients and decreased remitting, seven with secondary progressive, 15 with primary detection in three others; for three patients where progressive and three with transitional multiple sclerosis). enhancement was noted, there was no difference. With triple-
The number of enhancing lesions detected with short-delay dose studies, MT imaging increased detection of enhancing MT imaging following single-dose Gd-DTPA was 132 (with lesions in eight patients and decreased detection in three 10 active studies), compared with 154 enhancing lesions others; for four patients where enhancement was noted, there detected (and a single additional active study) with early was no difference.
non-MT triple-dose studies. These differences were not statistically significant.
Comparison of MT and triple-dose Gd-DTPA Effects of combining MT, triple-dose Gd-DTPA
The effect of early single-dose MT imaging was compared with early triple-dose non-MT imaging in 43 patients studied and delayed imaging (six with benign, 11 with relapsing-remitting, seven with The combination of triple-dose Gd-DTPA, MT contrast and long delay was compared with conventional, early singlesecondary progressive, 16 with primary progressive and three dose, non-MT imaging in 35 patients studied (five with In benign, relapsing-remitting, secondary progressive and transitional multiple sclerosis, delayed MT imaging followbenign, nine with relapsing-remitting, five with secondary progressive, 13 with primary progressive and three with ing triple-dose Gd-DTPA detected more enhancing lesions than early non-MT imaging with the single dose. With long transitional multiple sclerosis). The use of such a combination resulted in an overall 126% increase in the number of delays, this increase was not statistically significant for any multiple sclerosis subgroup. For short delays, howenhancing lesions detected, the greatest of any approach studied (90 with early single-dose non-MT imaging versus ever, increases were significant for both relapsing-remitting (P Ͻ 0.05, Wilcoxon matched-pairs signed rank sum test) 196 with long-delay triple-dose MT imaging; P Ͻ 0.05, Wilcoxon matched-pairs signed rank sum test). For these 35 and secondary progressive multiple sclerosis subgroups (P Ͻ 0.05, Wilcoxon matched-pairs signed rank sum test). patients, the number of active studies increased from eight to 10 with this combined approach (two patients with benign, one each with relapsing-remitting and transitional multiple sclerosis were active only with the triple dose, MT
Discussion
We have demonstrated that triple-dose (0.3 mmol/kg) Gdand long delay; one patient each with primary progressive and secondary progressive multiple sclerosis were active only DTPA, MT contrast and delayed imaging all affect the number of enhancing lesions detected in multiple sclerosis. with early, non-MT, single-dose studies).
The combination of triple-dose Gd-DTPA, MT contrast The most sensitive combination, MT contrast imaging between 40 and 60 min after administration of triple-dose and short delay detected 118% more enhancing lesions than early non-MT single-dose studies (P Ͻ 0.002, Wilcoxon
Gd-DTPA, resulted in a 126% increase in the overall number of enhancing lesions detected over non-MT, early, singlematched-pairs signed rank sum test) (Table 5) . For these 39 patients, the number of active studies increased from 10 to dose imaging (the conventional approach in current use); a shorter delay of 20-40 min resulted in a marginally smaller 14 (two patients with benign, and one each with relapsingremitting, secondary progressive and transitional multiple increase (118%). While the advantage of combining these techniques is sclerosis were active only with triple-dose Gd-DTPA, MT and short delay; one patient with primary progressive multiple clear, some MRI units normally participating in treatment trials may have difficulties using all three methods, because sclerosis was active only with early single-dose, non-MT imaging). of financial, time or software limitations. In addition, the post-marketing surveillance of triple-dose Gd-DTPA is extremely enhancing lesions detected, by 47% for the single dose and 27% for the triple dose. The number of enhancing lesions limited compared with that of single-dose administration. We detected was not significantly further increased by a long attempted to assess individual effects of each technique. In delay, although there was a trend towards this with the isolation, only triple-dose Gd-DTPA resulted in significantly triple dose. increased enhancing lesion detection (75% more than with Previous groups have suggested that, in multiple sclerosis, the single dose). Delayed or MT imaging alone did not result the use of MT with single-dose Gd-DTPA may result in an in significant improvements at either single-or triple-dose improvement in contrast comparable to that given by tripleGd-DTPA, although it is possible they might have, had we dose Gd-DTPA, thereby avoiding the higher cost of the latter looked at a larger number of patients. The combination of a and the possibility of more side effects at this higher dose short delay and MT did significantly increase the number of (Finelli et al., 1994) . However, in our study, non-MT imaging with a triple dose significantly increased the number of enhancing lesions detected, by 34%, when compared with MT imaging following single-dose Gd-DTPA. We have observed more adverse events, possibly attributable to Gd-DTPA, using the triple dose: seven (14%) with the triple dose in 50 patients versus one (2%) with the single dose in 48 patients. All these were relatively minor and self-limiting, and it is possible that some were incidental and unrelated to injection of contrast medium. Some of these reactions (i.e. urticaria, vomiting, flushing, paraesthesiae and headache) are well described with Gd-DTPA (Niendorf et al., 1993) . The frequency of 2% of possible/probable side effects associated with 0.1 mmol/kg is comparable with that in other studies (Niendorf et al., 1993) . A review of studies investigating the safety of 0.1 mmol/kg concluded that the overall frequency of adverse events is in the order of 1% and comparable to that of intravenous physiological saline (Niendorf et al., 1993) . In a randomized trial of 199 patients comparing 0.1 mmol/kg and 0.3 mmol/kg Gd-DTPA, a much higher frequency of adverse events with 0.1 mmol/kg was observed (6%), equal to that associated with 0.3 mmol/kg Gd-DTPA (Haustein et al., 1993) . In that trial, there was no suffered any adverse events following the second session (0.1 mmol/kg). Without the late assessment at the second improved using a combination of triple-dose Gd-DTPA and delayed MT imaging, up to 126% over standard single-dose imaging session we would have missed three possible adverse events following the triple dose. Previous authors have imaging, this effect differed between subgroups. Compared with standard early non-MT imaging following single-dose suggested that a history of allergy may predispose patients to a higher risk of adverse events following Gd-DTPA Gd-DTPA, the combination of a short delay, MT and tripledose Gd-DTPA significantly increased detection of enhancing administration (Niendorf et al., 1993) . In addition, information from post-marketing surveillance revealed one lesions in patients with relapsing-remitting and secondary progressive multiple sclerosis. In 22 patients with relapsingdeath from anaphylactic shock in a patient with asthma (Niendorf et al., 1993) . Whilst previous reports suggest that remitting and secondary progressive multiple sclerosis, we noted that the triple dose alone resulted in a 70% increased adverse events are not dose-related (Haustein et al., 1993; Niendorf et al., 1993) , caution should be maintained regarding yield in enhancing lesions over single-dose Gd-DTPA, which is comparable to the results of a previous study, where a those patients at potential risk (e.g. allergies, asthma) until more data are available. In this study, it is possible that the 66% increase was observed (Filippi et al., 1996a) . In our study, many more enhancing lesions were seen in patients use of bolus Gd-DTPA rather than an infusion contributed to the increased frequency of adverse events noted with the with relapsing-remitting and secondary progressive multiple sclerosis than in those with benign disease, regardless of higher contrast dose. In multiple sclerosis, where the time to reach maximal enhancement is relatively long compared with imaging modality or dose of Gd-DTPA. This is in keeping with previous studies using delayed imaging and triple dose many other pathologies, the use of an infusion over a few minutes might not be too detrimental to the sensitivity.
Gd-DTPA (Filippi et al., 1996a, b) . However, in the 16 patients with primary progressive Further studies into tolerance of triple-dose Gd-DTPA would be useful, and these might address such issues. If triple-dose multiple sclerosis, little enhancement was seen with any approach (no more than two enhancing lesions were noted Gd-DTPA is to be used for serial assessment in treatment trials, then any potential increase in power of the study for any particular combination). These findings are discordant with a recent study comparing the combined effects of delay should be weighed against a potential for increased sideeffects that may reduce patient compliance and cause and triple-dose Gd-DTPA with single-dose MRI in 10 patients with primary progressive disease, in which four enhancing premature withdrawal.
In the present study, the MT sequence was designed to lesions (two active studies) were seen with single-dose Gd-DTPA, 13 enhancing lesions (five active studies) with early allow lesions to become less hypointense or disappear, compared with standard T 1 -weighted images. The MT triple-dose Gd-DTPA and 14 enhancing lesions (six active studies) 1 h after triple-dose Gd-DTPA (Filippi et al., 1995) . presaturation pulse for this sequence resulted in a 16.8% mean reduction in signal intensity for normal white matter,
The reasons for this discrepancy are not clear. It is unlikely that different imaging parameters contribute; the main as determined in a separate study of three healthy subjects. Other studies using more powerful MT presaturation pulses, difference was our use of 3 mm rather than 5 mm slices, but this might be expected to increase rather than decrease where signal intensity of normal-appearing white matter has been reduced by 35-37%, have reported frequent high signal detection, as has been shown with three-dimensional T 1 -weighted gradient echo sequences in multiple sclerosis from multiple sclerosis lesions prior to administration of gadolinium contrast medium (Finelli et al., 1994; Mehta (Filippi et al., 1996c) . With small studies, there is a possibility of selection bias, although we have studied 16 patients with et al., 1995) . In order to define enhancing lesions in this situation, signal to noise evaluation before and after contrast a negative result. There were differences in clinical parameters between the two studies, our subjects having a longer disease medium is desirable, but may be time consuming. Where less powerful MT sequences are used, as in our study, this duration (9 versus 6.5 years) and being relatively more disabled (median EDSS 7.5 versus 4.6). In addition, the situation does not arise, and straightforward comparison of images before and after contrast medium should suffice. This diagnosis of primary progressive multiple sclerosis is historical, and therefore it is difficult to be absolutely certain approach may also confer an advantage for acquisition, allowing a greater number of thinner slices without exceeding about the absence of transient neurological episodes before onset of the progressive course. radiofrequency deposition limits. Whichever approach is used, we feel that acquisition of a pre-injection MT-prepared Our findings in the primary progressive group raise the possibility that the pathological substrate of the slow T 1 -weighted image is essential for analysis of MT-prepared contrast-enhanced images; imaging parameters before and progression in disability may be independent of blood-brain barrier disruption. Pathological studies have, however, shown after injection should be identical, with no changes in transmitter or receiver gain, and, for visual assessment of inflammatory activity in patients with primary progressive multiple sclerosis, albeit less intense than in those with enhancing lesions, window levels should remain constant. All these factors were carefully controlled in our study. secondary progressive disease (Revesz et al., 1994) . In relapsing-remitting and secondary progressive multiple Within the context of treatment trials, it is important to consider the disease subgroups of multiple sclerosis. Whilst sclerosis, the presence of gadolinium enhancement within lesions has been correlated with evidence of inflammation the overall detection of enhancing lesions was significantly and active demyelination, as demonstrated by pathological When considering 'activity' (i.e. the presence of at least one examination of tissue obtained from post-mortem or enhancing lesion), it is likely that delayed imaging will have stereotaxic biopsy (Nesbit et al., 1991; Katz et al., 1993;  different effects for different lesions; this would account for Rodriguez et al., 1993) . It appears that, in primary progressive the variable effect of delay on activity noted in this study, multiple sclerosis, the milder inflammatory changes are where certain patients were designated active only on early generally not associated with evident changes in blood-brain images. In this study, MT imaging appeared to result in an barrier permeability to gadolinium based contrast media.
overall trend towards increased detection of enhancing Studies of the blood-brain barrier using CSF markers lesions, although individual patients responded differently. nevertheless suggest that some disruption is commonly Whilst the individual effect of MT imaging might be expected present (McLean et al., 1993) , but do not differentiate to differ according to the amount of tissue disruption both between focal or diffuse changes in blood-brain barrier within the enhancing lesion and surrounding tissue, the lesion disruption. Whereas focal changes might result in visible conspicuity should theoretically always be comparable or enhancing lesions (contrasting with surrounding nonimproved. In this study, MT imaging appeared to show fewer inflammatory tissue), diffuse disruption might be expected enhancing lesions than non-MT imaging in a minority of to cause subtle widespread intensity changes not apparent on patients. Whilst differing degrees of flow artefact between visual evaluation. This might be studied using coregistration the different imaging techniques might possibly account for and subtraction methods on images before and after contrast this, it is more likely that small differences in imaging time medium. Such analysis will be the subject of a future report.
following contrast-medium injection are responsible. The The study results have direct relevance to the use of study was designed to minimize such effects, in that gadolinium-enhanced MRI as an indicator of therapeutic corresponding MT and non-MT images were acquired within efficacy in treatment trials. Whilst we have shown that the 10 min of each other for each timepoint, and patients were number of enhancing lesions detected may be significantly alternated with respect to whether the post-contrast imaging increased in relapsing-remitting and secondary progressive sequence commenced with MT or non-MT imaging. Such subgroups using the above methods, this has not been differences in time of acquisition might account for individual paralleled by such noticeable increases in the number of patient variability, whilst the overall effect of MT in the active studies. Indeed, some active studies with standard whole group should be minimally affected due to the number techniques were designated inactive with potentially more of patients studied. sensitive techniques. It is possible that minor amounts of For any potential imaging technique to confer an advantage patient movement during the study might have influenced over existing methods, it should not only be more sensitive the detection of small enhancing lesions. This may also but should also have comparable or improved reliability. reflect potential difficulties in interpreting areas of high Previous authors have shown comparable inter-rater signal, and in differentiating contrast enhancement from reproducibility for assessment of single-dose, triple-dose and artefact. Such difficulties were highlighted by the results 1 h delayed triple-dose images (Filippi et al., 1996d) . The from the reported patient with primary progressive multiple reliability of MT imaging and combined MT, delayed triplesclerosis who showed activity with conventional early nondose imaging is currently being evaluated and will be the MT single-dose imaging alone. Retrospective analysis subject of a future report. confirmed a small focal area of high signal in the left Another key question that remains to be answered is hemisphere on these images (with an underlying area of whether serial studies with triple-dose contrast medium would T 2 /proton-density weighted hyperintensity), whilst subsedetect more lesions overall than those seen with serial quent images from the completed series confirmed this as a single-dose imaging. Possible explanations for the increased likely false positive result, with more obvious flow artefact sensitivity with cross-sectional evaluation include that (i) arising from the third ventricle in this same region. Whilst more new enhancing lesions are seen, or (ii) the same number imaging with triple-dose Gd-DTPA would always be of enhancing lesions are seen but they enhance for longer, expected to increase visible enhancement compared with i.e. on serial studies there will be more persistently enhancing the single dose (Tofts, 1996) , techniques such as MT and lesions. Serial studies are required to resolve this. delayed imaging might be expected to have different effects
The findings in this and other studies indicate that tripleupon different lesions. This is especially likely with delayed dose Gd-DTPA, MT contrast and delayed imaging probably imaging, where the time for optimal enhancement will depend all increase the sensitivity of contrast-enhanced MRI studies on lesion size and the degree of blood-brain barrier deficit in relapsing-remitting and secondary progressive multiple (Tofts, 1996) . In a study of patients with relapsingsclerosis, although the gain is greatest from the use of the remitting and secondary progressive multiple sclerosis, it has triple dose. In contrast, in primary progressive multiple been shown that delayed imaging 1 h following Gd-DTPA sclerosis, such methods are unlikely to be useful. Further administration significantly increases the number of studies are required to evaluate the reproducibility and enhancing lesions detected that are over 10 mm 2 , whilst longitudinal sensitivity of such combinations; the choice of smaller lesions may be better detected if imaging immediately follows Gd-DTPA administration (Filippi et al., 1996a) . optimal technique will require consideration of multiple 
